NewsBenzingaLongeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome Benzinga 2026.10.26 13:18 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Neutral on Farmers & Merchants, Raises Price Target to $39 Elon Musk's $40 Billion Terrestrial Data Center Pivot Draws Fire From Short Seller Jim Chanos After 'Orbital' IPO Hype: '...Pretty Material $500B Question' Wedbush Maintains Outperform on VeriSign, Raises Price Target to $367 EQT, Range Resources Mega-Merger Set to Create US Gas Juggernaut Wells Fargo Upgrades NorthWestern Energy Group to Overweight, Raises Price Target to $90 Ponce Finl Gr Q3 EPS $0.76 Misses $9.40 Estimate, Sales $34.839M Beat $6.360M Estimate
Elon Musk's $40 Billion Terrestrial Data Center Pivot Draws Fire From Short Seller Jim Chanos After 'Orbital' IPO Hype: '...Pretty Material $500B Question'
